NKB2 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - TG Therapeutics Inc

Watchlist Manager

Watchlist

Price: 47.4 EUR -0.42%

Market Cap: €7.3B

T	TG Therapeutics Inc F:NKB2	US
R	Rex Trueform Group Ltd JSE:RTN	ZA
B	Bastei Luebbe AG XMUN:BST	DE
Q	Quart Development SA WSE:QRT	PL
B	Bastei Luebbe AG F:BST	DE
	Corona Remedies Ltd NSE:CORONA	IN
	Constellation Resources Ltd F:0XX	AU

Profitability Summary

TG Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

82%

Strong 3Y Average Gross Margin

89%

Declining Gross Margin

88% > 82%

Healthy Operating Margin

17%

Sustainable 3Y Average Operating Margin

14%

Operating Margin is Increasing

-701% > 17%

Exceptional Net Margin

55%

Sustainable 3Y Average Net Margin

28%

Net Margin is Increasing

-730% > 55%

Healthy Free Cash Flow Margin

Negative 3Y Average Free Cash Flow Margin

-6%

Free Cash Flow Margin is Increasing

-666% > 2%

Exceptional ROE

100%

Exceptional 3Y Average ROE

Exceptional 3Y Average ROIC

71%

ROIC is Increasing

-1 063% > 100%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.